What are the uses and dosages of immunosuppressants, such as tacrolimus (FK506), cyclosporine, methotrexate, azathioprine, and rituximab, in patients with autoimmune diseases or undergoing organ transplantation?

Immunosuppressants in Organ Transplantation and Autoimmune Disease

Standard Immunosuppressive Regimens for Organ Transplantation

The cornerstone of immunosuppression after solid organ transplantation consists of a calcineurin inhibitor (CNI), an antiproliferative agent, and corticosteroids, with induction therapy using a biologic agent. 1

Induction Therapy

• Use an IL-2 receptor antagonist (basiliximab or daclizumab) as first-line induction therapy for standard-risk transplant recipients 1, 2
• Reserve lymphocyte-depleting agents (alemtuzumab, antithymocyte globulin) for high immunologic risk patients, including those with high panel reactive antibodies, repeat transplants, or African-American recipients in certain scenarios 1, 2
• Induction therapy should be administered before or at the time of transplantation 1

Calcineurin Inhibitors (CNIs)

Tacrolimus (FK506) is the preferred first-line CNI over cyclosporine due to superior efficacy in preventing acute rejection and improved graft survival 1, 2

Tacrolimus Dosing:

• Initial dose: 0.1 mg/kg/day divided every 12 hours when combined with IL-2 receptor antagonist and mycophenolate 2
• Higher doses (0.2 mg/kg/day divided every 12 hours) are required without induction therapy when combined with azathioprine 2
• Target trough levels: 5-10 ng/mL (avoid historically recommended 10-15 ng/mL levels which increase nephrotoxicity without improving rejection rates) 2
• Monitor trough levels every other day immediately post-operative until target reached, then with any medication changes or clinical status changes 1, 2
• Tacrolimus is metabolized via CYP3A4 and P-glycoprotein pathways 1, 3

Cyclosporine Dosing:

• Cyclosporine should be started before or at the time of transplantation 1
• Blood concentration monitoring is essential to avoid toxicity and prevent rejection 4
• Critical warning: Cyclosporine modified formulations (Neoral, Gengraf) are NOT bioequivalent to Sandimmune and cannot be used interchangeably 4

Antiproliferative Agents

Mycophenolate mofetil (MMF) is the preferred first-line antiproliferative agent over azathioprine 1, 2

Mycophenolate Mofetil:

• Standard dose: 1 gram twice daily in combination with tacrolimus and corticosteroids 3
• MMF selectively inhibits inosine monophosphate dehydrogenase (IMPDH), blocking T and B lymphocyte proliferation 1
• Has minimal drug-drug interactions with COVID-19 therapies and other immunosuppressants 1

Azathioprine:

• Alternative antiproliferative agent when MMF is not tolerated or for cost considerations 1
• Critical interaction: Allopurinol increases azathioprine to toxic levels—avoid this combination or reduce azathioprine dose by 75% 1
• Dose range typically 1-3 mg/kg/day 3

Corticosteroids

• Administer high doses during the first week post-transplant, then rapidly taper to low levels 1
• In low immunologic risk patients receiving induction therapy, corticosteroids may be discontinued during the first week after transplantation 1
• For patients with autoimmune liver diseases (autoimmune hepatitis, primary biliary cirrhosis) or recurrent rejection, continue steroids indefinitely 1
• If continued beyond the first week, maintain rather than withdraw to reduce rejection risk 1

mTOR Inhibitors (Alternative Agents)

Sirolimus (rapamycin) and everolimus should NOT be started until graft function is established and surgical wounds are healed 1, 2

Sirolimus:

• Inhibits T cell proliferation through cell cycle inhibition rather than calcineurin pathway 1
• Used as alternative to CNIs or in combination with lower CNI doses to reduce nephrotoxicity 1
• Metabolized via CYP3A4 pathway like tacrolimus and cyclosporine 1

Long-Term Maintenance Strategy

• Reduce to the lowest planned doses of maintenance immunosuppression by 2-4 months post-transplant if no acute rejection has occurred 1, 2
• Continue CNIs indefinitely rather than withdrawing them—withdrawal increases rejection risk 1
• Target the lowest effective doses to minimize long-term toxicity while preventing rejection 1

Critical Drug Interactions

Medications That INCREASE CNI Levels (Risk of Toxicity):

Avoid or use extreme caution with CYP3A4 inhibitors: 1

• Lopinavir-ritonavir: Reduce tacrolimus dose to 2-5% of baseline due to potent CYP3A4 inhibition 1
• Azole antifungals (ketoconazole, itraconazole, fluconazole)
• Macrolide antibiotics (erythromycin, clarithromycin)
• Calcium channel blockers (diltiazem, verapamil)
• Carvedilol (inhibits P-glycoprotein pathway) 1

Medications That DECREASE CNI Levels (Risk of Rejection):

Avoid CYP3A4 inducers: 1

• Anticonvulsants: carbamazepine, phenobarbital, phenytoin
• Antibiotics: rifampin, rifabutin
• St. John's Wort
• Orlistat

Medications That Potentiate CNI Toxicity:

• NSAIDs: Avoid entirely—potentiate CNI-induced nephrotoxicity 1
• Spironolactone: Increases CNI-induced hyperkalemia 1

Monitoring Parameters

Essential Laboratory Monitoring:

• Drug trough levels (tacrolimus, cyclosporine, sirolimus) 1, 2
• Renal function (serum creatinine, eGFR) 1, 3
• Blood pressure 1, 3
• Glucose and diabetes screening 1, 3
• Electrolytes: potassium, magnesium, phosphate 1, 3
• Lipid panel 1, 3
• Complete blood count 1, 3
• Liver function tests 1

Monitoring for Complications:

• Nephrotoxicity occurs in approximately 52% of kidney transplant patients on tacrolimus 3
• If renal dysfunction develops, reduce target CNI concentration 1
• Monitor for infections (occurs in 45-49% of patients), hypertension (50-52%), and diabetes mellitus (9-24% depending on regimen) 3

Special Populations and Circumstances

Autoimmune Liver Disease:

• Patients with autoimmune hepatitis, primary biliary cirrhosis, or primary sclerosing cholangitis require indefinite corticosteroid therapy 1
• These patients are at higher risk for early and late cellular rejection compared to other transplant indications 1
• Consider basiliximab induction and long-term triple immunosuppression (tacrolimus + mycophenolate + low-dose prednisolone 5 mg daily) 1

Immunocompromised Patients with Autoimmune Disease:

• Azathioprine, cyclosporine, methotrexate, corticosteroids, and cyclophosphamide are used for various autoimmune conditions 1, 5
• TNF-α antagonists (infliximab, adalimumab) carry higher infection risk than etanercept 1
• Rituximab (anti-CD20 monoclonal antibody) is used for refractory autoimmune conditions and certain malignancies 6, 7

COVID-19 Considerations:

• Immunosuppression does not appear to worsen COVID-19 outcomes and may theoretically prevent cytokine storm progression 1
• If lopinavir-ritonavir is used for COVID-19, reduce tacrolimus to 2-5% of baseline dose 1
• Defer clinic visits for 14 days in patients with COVID-19 symptoms, but ensure medication refills to avoid acute withdrawal 1

Common Pitfalls to Avoid

• Never interchange cyclosporine modified formulations with Sandimmune without physician supervision—they are not bioequivalent 4
• Always notify the transplant center before prescribing any new medication due to narrow therapeutic windows and extensive drug interactions 1
• Avoid all NSAIDs in transplant recipients—they potentiate CNI nephrotoxicity 1
• Do not start mTOR inhibitors until wounds are healed and graft function is established 1
• Reduce allopurinol dose or avoid entirely when used with azathioprine 1
• Monitor for hypogammaglobulinemia (IgG <600 mg/dL) which increases infection risk and impairs vaccine response 1

Infection Prophylaxis

Pneumocystis jiroveci prophylaxis is mandatory with tacrolimus and other immunosuppressive regimens 1